HDAC6-IN-44

HDAC6-IN-44 (compound H10) is a selective HDAC6 inhibitor with an IC50 value of 8.97 nM. HDAC6-IN-44 can inhibit the idiopathic pulmonary fibrosis (IPF) phenotype and exhibits antifibrotic activity. Additionally, HDAC6-IN-44 reduces fibrogenesis in a bleomycin-induced pulmonary fibrosis mouse model and demonstrates good metabolic stability. HDAC6-IN-44 holds promise for research in the field of idiopathic pulmonary fibrosis[1].

Product Specifications

UNSPSC

12352005

Target

HDAC

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Epigenetics

Applications

COVID-19-anti-virus

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/hdac6-in-44.html

Smiles

O=C(NO)C1=CC=C(CN2C([C@@](CCC3)([H])N3CC4=CC=CC=C42)=O)C=C1

Molecular Formula

C20H21N3O3

Molecular Weight

351.40

References & Citations

[1]Li Y, et al. Discovery of novel pyrrolo[2,1-c][1,4]benzodiazepine-3,11-dione (PBD) derivatives as selective HDAC6 inhibitors for the efficient treatment of idiopathic pulmonary fibrosis (IPF) in vitro and in vivo. Eur J Med Chem. 2024 Jun 17;275:116608.